Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer.
Aged
Aged, 80 and over
Antigens, Surface
/ blood
Dose Fractionation, Radiation
Feasibility Studies
Glutamate Carboxypeptidase II
/ blood
Humans
Magnetic Resonance Imaging
/ methods
Male
Middle Aged
Neoplasm Recurrence, Local
/ blood
Positron Emission Tomography Computed Tomography
Prospective Studies
Prostatic Neoplasms
/ blood
Radiation Injuries
/ pathology
Radiosurgery
/ adverse effects
Re-Irradiation
/ adverse effects
Salvage Therapy
/ methods
Time Factors
Treatment Outcome
Journal
International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
received:
29
04
2020
revised:
23
06
2020
accepted:
04
07
2020
pubmed:
14
7
2020
medline:
16
4
2021
entrez:
14
7
2020
Statut:
ppublish
Résumé
To report the feasibility, toxicity, and preliminary outcomes (metabolic and biochemical) of From March 2016 to March 2019, 25 patients were enrolled in a prospective single institution trial (ACTRN12617000035325). Eligibility criteria included patients with biopsy proven isolated prostate recurrence after definitive irradiation, with concordant multiparametric MRI and Median age was 72 years (range, 62-83) with a median time between first radiation treatment and salvage SBRT of 8.3 years (range, 4.5- 13.6). Median prostate-specific antigen at reirradiation was 4.1 (range, 1.1-16.6). The median follow-up was 25 months (range, 13-46). Acute grade 1 and 2 genitourinary (GU) toxicity occurred in 6 (24%) and 1 (4%) men, respectively. Acute grade 1 gastrointestinal (GI) toxicity occurred in 8% with one acute grade 3 GI toxicity (4%) due to a rectal ulcer overlying the hydrogel. Late grade 1 and 2 GU toxicity occurred in 28% and 4%. Late grade 1 GI toxicity occurred in 8% with no grade 2 or greater toxicity. Twenty-four patients have undergone per-protocol 12-month PSMA-directed salvage focal reirradiation to the prostate using linear accelerator-based SBRT is feasible and safe. Toxicity was low, with very favorable short term local and biochemical control in a carefully selected cohort of patients.
Identifiants
pubmed: 32659332
pii: S0360-3016(20)31412-7
doi: 10.1016/j.ijrobp.2020.07.014
pii:
doi:
Substances chimiques
Antigens, Surface
0
FOLH1 protein, human
EC 3.4.17.21
Glutamate Carboxypeptidase II
EC 3.4.17.21
Banques de données
ANZCTR
['ACTRN12617000035325']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1172-1178Informations de copyright
Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.